DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01135
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB01135
Doxacurium chloride (formerly recognized as BW938U80 or BW A938U) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia for endotracheal intubation or to facilitate mechanical ventilation. Unlike a number of other related skeletal muscle relaxants, it is rarely used adjunctively to facilitate endotracheal intubation. Doxacurium chloride is a mixture of three trans, trans stereoisomers, a dl pair [(1R,1'R ,2S,2'S ) and (1S,1'S ,2R,2'R )] and a meso form (1R,1'S,2S,2'R). NUROMAX binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Originator
Sources: http://en.academic.ru/dic.nsf/enwiki/3078883
Curator's Comment: synthesized by Mary M. Jackson and James C. Wisowaty, PhD (both chemists within the Chemical Development Laboratories at Burroughs Wellcome Co., Research Triangle Park, NC) in collaboration with John J. Savarese MD (who at the time was an anesthesiologist in the Dept. of Anesthesia, Harvard Medical School at the Massachusetts General Hospital, Boston, MA).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362997 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | NUROMAX Approved UseNUROMAX is a long-acting neuromuscular blocking agent, indicated to provide skeletal muscle
relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical
ventilation. Launch Date1991 |
|||
| Preventing | NUROMAX Approved UseNUROMAX is a long-acting neuromuscular blocking agent, indicated to provide skeletal muscle
relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical
ventilation. Launch Date1991 |
Sample Use Guides
adults: An initial NUROMAX dose of 0.08 mg/kg (3 × ED95) should be reserved for instances in which a need for very prolonged neuromuscular block is anticipated.
Children:
When administered during halothane anesthesia, an initial dose of 0.03 mg/kg (ED95) produces maximum neuromuscular block in about 7 minutes (range: 5 to 11) and clinically effective block for an average of 30 minutes (range: 12 to 54).
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QM03AC07
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
||
|
WHO-ATC |
M03AC07
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
||
|
NCI_THESAURUS |
C29696
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M78TVM3G5Z
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
C65472
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
100000080770
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
49275
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
m4750
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
6205
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
SUB06380MIG
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
DOXACURIUM CHLORIDE
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
83348-52-1
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
DBSALT002766
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
Z-9
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
CHEMBL1237123
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY | |||
|
4707
Created by
admin on Wed Apr 02 09:23:56 GMT 2025 , Edited by admin on Wed Apr 02 09:23:56 GMT 2025
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SUBSTANCE RECORD